Amgen Inc. (AMGN)

199.12
3.60 1.80
NASDAQ : Health Technology
Prev Close 202.73
Open 197.56
Day Low/High 196.00 / 201.38
52 Wk Low/High 166.30 / 244.99
Volume 718.37K
Avg Volume 3.14M
Exchange NASDAQ
Shares Outstanding 589.81M
Market Cap 116.94B
EPS 13.00
P/E Ratio 16.19
Div & Yield 6.40 (3.00%)

Latest News

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

It's no secret that the Fed would like to get out of the short-term repo business.

Market Prices in New Risk, Action for 9 Stocks in My Portfolio: Market Recon

Market Prices in New Risk, Action for 9 Stocks in My Portfolio: Market Recon

What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead

AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far

Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon

Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

We Prescribe Amgen to Treat Your Portfolio

We Prescribe Amgen to Treat Your Portfolio

According to the charts, the drugmaker should break out to new highs.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

Real Money Post-Industrial Average Continues to Outpace Major Indices

Real Money Post-Industrial Average Continues to Outpace Major Indices

RMPIA is up 20.9% in the first nine months of 2019.

Jim Cramer: How to Survive This Violent Rotation

Jim Cramer: How to Survive This Violent Rotation

Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.

Could Small Drug Trial Hold Big Potential for Amgen?

Could Small Drug Trial Hold Big Potential for Amgen?

The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Amgen's Lower Open Tests Support but the Bigger Picture Is More Important

Let's check out the charts to get a sense of where prices could be headed.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Real Money Post-Industrial Average Holds Own in Turbulent August

Real Money Post-Industrial Average Holds Own in Turbulent August

Gains in Amgen, CVS, and others helped offset declines in other stocks, as the RMPIA rose over the last two months to 0.6%, handily beating all the major domestic stock market averages.

The Market Has Fury for a Suitor Scorned

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.